Expanding the market into Asia pacific region, and great market development scope in the emerging and untapped markets like MEA and Latin America where there is increase in the prevalence of various respiratory diseases such as COPD, bronchiectasis, asthma, and other respiratory diseases is a key opportunity for the market players. Emerging economies such as India, China, Brazil, and Eastern Europe create growth opportunity for the global airway clearance devices market over the forecast year due to surge in the geriatric population, rise in disposable income, and development of healthcare infrastructure in the forthcoming years

Report titled “Global Health Insurance Market Driven by COVID 19 and Outlook to 2027 provides a holistic perspective of past, present and future market performance The study comprises of market dynamics that offers an understanding of the industry trends, driving forces, major challenges hampering the growth and also an analysis of the future opportunities which will help market players to leverage untapped business potential A Global health insurance policy covers services such as chronic illness treatment, psychiatric care, diagnosis, dental care, emergency evacuation, and others It usually charges a specified sum from the individual and pays for the policyholder's surgical and medical expenses

Opinion helped us to explore specific quantitative information related to market scenario of Global Mattress Industry specific to average cost per mattress, household vs commercial mattresses, demand by type of mattresses, and other factors

Expert Opinion helped us to explore specific quantitative information related to market scenario of Global Mattress Industry specific to average cost per mattress, household vs commercial mattresses, demand by type of mattresses, and other factors We have approached the industry experts and key retailers in both online and offline channel Great amount of actionable insights have also been gathered from industry suppliers

1）中医药：持续看好中药高质量发展大逻辑，在政策支持和国民认可度逐步提高的大环境下，有望逐步出现市场规模和个股业绩增长的实质变化；2）创新药：关注院内复苏方向，药品板块建议关注集采出清、业绩触底反弹、去年二季度业绩低基数的仿创转型公司；二季度AACR 及ASCO 会议先后召开，国内外医药创新进入高质量高标准的新阶段，看好具有技术平台及出海潜力的公司；3）CXO：看好全球投融资在今年下半年持续改善、创新需求持续恢复，我们预计二季度公司业绩将整体符合预期增长，下半年国际化CXO头部企业将受益于海外复苏而开启新一轮增长。建议重点关注平台型龙头、细分领域龙头。同时GLP-1 药物的持续放量为多肽产业链带来新的增长机遇，关注相关产业链机遇。

集采常态化下，机遇与挑战并存。集采政策影响范围持续扩大，一方面集采可能压缩企业利润空间，在产品同质化竞争激烈的背景下，创新能力不足且成本控制能力较差的企业或将面临被淘汰的生存危机；另一方面，对于产品竞争力强、价格优势显著的企业，集采有望提供抢占市场份额、实现国产替代的弯道超车机会。集采常态化倒逼参与者加大创新研发投入，提升成本控制能力，助力行业健康发展。

总体来看，医药板块从估值和持仓来看处于历史低位，随着院内诊疗的持续复苏，医药板块整体经营情况持续向上，看好下半年中医药、院内复苏和医药创新等方向。